1
|
Morelli F, Balzarotti N, Guarischi M, Cappagli G, Maviglia A, Crepaldi M, Orciari L, Parmiggiani A, Catalano G, Signorini S, Gori M. A novel multisensory device for the assessment and rehabilitation of perceptual and attentional competencies. Annu Int Conf IEEE Eng Med Biol Soc 2023; 2023:1-4. [PMID: 38083635 DOI: 10.1109/embc40787.2023.10340824] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/18/2023]
Abstract
The present study aims to assess a novel technological device suitable for investigating perceptual and attentional competencies in people with or without sensory impairment. The TechPAD is a cabled system including embedded sensors and actuators to enable visual, auditory, and tactile interactions and a capacitive surface receiving inputs from the user. The system is conceived to create multisensory environments, using multiple units controlled separately and simultaneously. We assessed the device by adapting a spatial attention task comparing performances in different cognitive load conditions (high or low) and stimulation (unimodal, bimodal, or trimodal). 28 sighted adults were asked to monitor both the central and peripheral parts of the device and to tap a target stimulus (either visual, auditory, haptic, or multimodal) as fast as they could. Our results suggest that this new device can provide congruent and incongruent multimodal stimuli and quantitatively measure parameters such as reaction time and accuracy, allowing to investigate perceptual mechanisms in multisensory environments.Clinical Relevance-The TechPad is a reliable tool for the assessment of spatial attention during interactive tasks. its application in clinical trials will pave the way to its role in multisensory rehabilitation.
Collapse
|
2
|
Cappagli G, Cuturi LF, Signorini S, Morelli F, Cocchi E, Gori M. Early visual deprivation disrupts the mental representation of numbers in visually impaired children. Sci Rep 2022; 12:22538. [PMID: 36581659 PMCID: PMC9800586 DOI: 10.1038/s41598-022-25044-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2022] [Accepted: 11/23/2022] [Indexed: 12/30/2022] Open
Abstract
Several shreds of evidence indicate that visual deprivation does not alter numerical competence neither in adults nor in children. However, studies reporting non-impaired numerical abilities in the visually impaired population present some limitations: (a) they mainly assessed the ability to process numbers (e.g. mathematical competence) rather than represent numbers (e.g. mental number line); (b) they principally focused on positive rather than negative number estimates; (c) they investigated numerical abilities in adult individuals except one focusing on children (Crollen et al. in Cognition 210:104586, 2021). Overall, this could limit a comprehensive explanation of the role exerted by vision on numerical processing when vision is compromised. Here we investigated how congenital visual deprivation affects the ability to represent positive and negative numbers in horizontal and sagittal planes in visually impaired children (thirteen children with low vision, eight children with complete blindness, age range 6-15 years old). We adapted the number-to-position paradigm adopted by Crollen et al. (Cognition 210:104586, 2021), asking children to indicate the spatial position of positive and negative numbers on a graduated rule positioned horizontally or sagittally in the frontal plane. Results suggest that long-term visual deprivation alters the ability to identify the spatial position of numbers independently of the spatial plane and the number polarity. Moreover, results indicate that relying on poor visual acuity is detrimental for low vision children when asked to localize both positive and negative numbers in space, suggesting that visual experience might have a differential role in numerical processing depending on number polarity. Such findings add knowledge related to the impact of visual experience on numerical processing. Since both positive and negative numbers are fundamental aspects of learning mathematical principles, the outcomes of the present study inform about the need to implement early rehabilitation strategies to prevent the risk of numerical difficulties in visually impaired children.
Collapse
Affiliation(s)
- G. Cappagli
- grid.25786.3e0000 0004 1764 2907Unit for Visually Impaired People (UVIP), Istituto Italiano di Tecnologia, Via Melen 83, 16100 Genova, Italy ,grid.419416.f0000 0004 1760 3107Developmental Neuro-Ophthalmology Unit, IRCCS Mondino Foundation, Pavia, Italy
| | - L. F. Cuturi
- grid.25786.3e0000 0004 1764 2907Unit for Visually Impaired People (UVIP), Istituto Italiano di Tecnologia, Via Melen 83, 16100 Genova, Italy ,grid.10438.3e0000 0001 2178 8421Department of Cognitive, Psychological, Pedagogical Sciences and of Cultural Studies, University of Messina, Messina, Italy
| | - S. Signorini
- grid.419416.f0000 0004 1760 3107Developmental Neuro-Ophthalmology Unit, IRCCS Mondino Foundation, Pavia, Italy
| | - F. Morelli
- grid.419416.f0000 0004 1760 3107Developmental Neuro-Ophthalmology Unit, IRCCS Mondino Foundation, Pavia, Italy ,grid.8982.b0000 0004 1762 5736Department of Brain and Behavioural Sciences, University of Pavia, Pavia, Italy
| | | | - M. Gori
- grid.25786.3e0000 0004 1764 2907Unit for Visually Impaired People (UVIP), Istituto Italiano di Tecnologia, Via Melen 83, 16100 Genova, Italy
| |
Collapse
|
3
|
Dartibale CB, Prado GDC, Carobeli LR, Meirelles LEDF, Damke GMZF, Damke E, Morelli F, Souza RP, da Silva VRS, Consolaro MEL. Recent HPV self-sampling use for cervical cancer screening in Latin America and Caribbean: a systematic review. Front Oncol 2022; 12:948471. [DOI: 10.3389/fonc.2022.948471] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/19/2022] [Accepted: 10/03/2022] [Indexed: 11/13/2022] Open
Abstract
ObjectiveCervical cancer is one of the deadliest cancers among women in Latin America and Caribbean (LAC), where most of the countries have not been successful in implementing population-level cytology-based screening programs. An increasing body of evidence supports the validity of self-sampling as an alternative to clinician collection for primary Human papillomavirus (HPV) screening. Therefore, this work aims to summarize recent HPV self-sampling approaches in LAC.MethodWe performed a systematic review to identify studies focused on “Self-sampling”, and “Human Papillomavirus DNA test” and “Latin America” in PubMed, Embase, Web of Science, Cochrane library and SCOPUS databases for publications dating between 01 January 2017 and 15 March 2022 based on the Preferred Reporting Items for systematic reviews and meta-analysis (PRISMA) statement. Additionally, the references of the articles were carefully reviewed.ResultsOf the 97 records selected, 20 studies including 163,787 participants, with sample sizes for individual studies ranging from 24 to 147,590 were included in this review. Studies were conducted in 10 LAC countries (18.5%), most with upper medium-income economies (70%). The range of age was 18 to ≥65 years. The vast majority of the studies (85%) addressed the HPV self-sampling strategy for primary cervical cancer screening with overall success for all women including under/never screened and those from special populations (rural, indigenous and gender minorities). Women generally found HPV self-sampling highly acceptable regardless of age, setting of collection, target population or country of residence.ConclusionsHPV self-sampling is a promising strategy to overcome the multiple barriers to cervical cancer screening in LAC settings and increasing attendance in underscreened women in countries/territories with well-established screening programs. Furthermore, this strategy is useful even in LAC countries/territories without organized cervical cancer screening and in special populations such as indigenous, rural and transgender women. Therefore, the information generated by the recent initiatives for HPV self-sampling approach in LAC can be beneficial for decision-making in both new and existing programs in the region.
Collapse
|
4
|
Secco S, Brambillasca P, Morelli M, Sampogna G, Alfonsi A, Morelli F, Solcia M, Dell’Oglio P, Olivero A, Palagonia E, Spinelli M, Bocciardi A, Rampoldi A, Galfano A. Efficacy of prostate artery embolization in patients with indwelling bladder catheter. EUR UROL SUPPL 2022. [DOI: 10.1016/s2666-1683(22)01155-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
|
5
|
Díaz M, Grim T, Markó G, Morelli F, Ibáñez-Alamo JD, Jokimäki J, Kaisanlahti-Jokimäki ML, Tätte K, Tryjanowski P, Møller AP. Author Correction: Effects of climate variation on bird escape distances modulate community responses to global change. Sci Rep 2021; 11:17975. [PMID: 34480085 PMCID: PMC8417276 DOI: 10.1038/s41598-021-97174-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Affiliation(s)
- M Díaz
- Department of Biogeography and Global Change, Museo Nacional de Ciencias Naturales (BGC-MNCN-CSIC), c/Serrano 115bis, 28006, Madrid, Spain.
| | - T Grim
- Department of Zoology and Laboratory of Ornithology, Palacky University, 77146, Olomouc, Czech Republic
| | - G Markó
- Behavioral Ecology Group, Department of Systematics, Zoology and Ecology, Eötvös Loránd University, Pázmány Péter sétány 1/c, 1117, Budapest, Hungary.,Department of Plant Pathology, Institute of Plant Protection, Hungarian University of Agriculture and Life Sciences, Ménesi út 44, 1118, Budapest, Hungary
| | - F Morelli
- Faculty of Environmental Sciences, Community Ecology and Conservation, Czech University of Life Sciences Prague, Kamýcká 129, 165 00, Prague 6, Czech Republic
| | - J D Ibáñez-Alamo
- Department of Zoology, Faculty of Sciences, University of Granada, 18071, Granada, Spain
| | - J Jokimäki
- Nature Inventory and EIA‑Services, Arctic Centre, University of Lapland, P. O. Box 122, 96101, Rovaniemi, Finland
| | - M-L Kaisanlahti-Jokimäki
- Nature Inventory and EIA‑Services, Arctic Centre, University of Lapland, P. O. Box 122, 96101, Rovaniemi, Finland
| | - K Tätte
- Department of Zoology, Institute of Ecology and Earth Sciences, University of Tartu, 19 51014, Tartu, Estonia
| | - P Tryjanowski
- Institute of Zoology, Poznań University of Life Sciences, Wojska Polskiego 71C, 60625, Poznań, Poland
| | - A P Møller
- Ecologie Systématique et Evolution, Université Paris-Saclay, CNRS, AgroParisTech, 91405, Orsay, France
| |
Collapse
|
6
|
Díaz M, Grim T, Markó G, Morelli F, Ibáñez-Alamo JD, Jokimäki J, Kaisanlahti-Jokimäki ML, Tätte K, Tryjanowski P, Møller AP. Effects of climate variation on bird escape distances modulate community responses to global change. Sci Rep 2021; 11:12826. [PMID: 34145317 PMCID: PMC8213824 DOI: 10.1038/s41598-021-92273-1] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2020] [Accepted: 06/01/2021] [Indexed: 11/13/2022] Open
Abstract
Climate and land use are rapidly changing environmental conditions. Behavioral responses to such global perturbations can be used to incorporate interspecific interactions into predictive models of population responses to global change. Flight initiation distance (FID) reflects antipredator behaviour defined as the distance at which an individual takes flight when approached by a human, under standardized conditions. This behavioural trait results from a balance between disturbance, predation risk, food availability and physiological needs, and it is related to geographical range and population trends in European birds. Using 32,145 records of flight initiation distances for 229 bird species during 2006–2019 in 24 European localities, we show that FIDs decreased with increasing temperature and precipitation, as expected if foraging success decreased under warm and humid conditions. Trends were further altered by latitude, urbanisation and body mass, as expected if climate effects on FIDs were mediated by food abundance and need, differing according to position in food webs, supporting foraging models. This provides evidence for a role of behavioural responses within food webs on how bird populations and communities are affected by global change.
Collapse
Affiliation(s)
- M Díaz
- Department of Biogeography and Global Change, Museo Nacional de Ciencias Naturales (BGC-MNCN-CSIC), c/Serrano 115bis, 28006, Madrid, Spain.
| | - T Grim
- Department of Zoology and Laboratory of Ornithology, Palacky University, 77146, Olomouc, Czech Republic
| | - G Markó
- Behavioral Ecology Group, Department of Systematics, Zoology and Ecology, Eötvös Loránd University, Pázmány Péter sétány 1/c, 1117, Budapest, Hungary.,Department of Plant Pathology, Institute of Plant Protection, Hungarian University of Agriculture and Life Sciences, Ménesi út 44, 1118, Budapest, Hungary
| | - F Morelli
- Faculty of Environmental Sciences, Community Ecology and Conservation, Czech University of Life Sciences Prague, Kamýcká 129, 165 00, Prague 6, Czech Republic
| | - J D Ibáñez-Alamo
- Department of Zoology, Faculty of Sciences, University of Granada, 18071, Granada, Spain
| | - J Jokimäki
- Nature Inventory and EIA-Services, Arctic Centre, University of Lapland, P. O. Box 122, 96101, Rovaniemi, Finland
| | - M-L Kaisanlahti-Jokimäki
- Nature Inventory and EIA-Services, Arctic Centre, University of Lapland, P. O. Box 122, 96101, Rovaniemi, Finland
| | - K Tätte
- Department of Zoology, Institute of Ecology and Earth Sciences, University of Tartu, 19 51014, Tartu, Estonia
| | - P Tryjanowski
- Institute of Zoology, Poznań University of Life Sciences, Wojska Polskiego 71C, 60625, Poznań, Poland
| | - A P Møller
- Ecologie Systématique et Evolution, Université Paris-Saclay, CNRS, AgroParisTech, 91405, Orsay, France
| |
Collapse
|
7
|
Fornarini G, Rebuzzi SE, Banna GL, Calabrò F, Scandurra G, De Giorgi U, Masini C, Baldessari C, Naglieri E, Caserta C, Manacorda S, Maruzzo M, Milella M, Buttigliero C, Tambaro R, Ermacora P, Morelli F, Nolè F, Astolfi C, Sternberg CN. Immune-inflammatory biomarkers as prognostic factors for immunotherapy in pretreated advanced urinary tract cancer patients: an analysis of the Italian SAUL cohort. ESMO Open 2021; 6:100118. [PMID: 33984678 PMCID: PMC8134706 DOI: 10.1016/j.esmoop.2021.100118] [Citation(s) in RCA: 30] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2021] [Revised: 03/04/2021] [Accepted: 03/17/2021] [Indexed: 12/18/2022] Open
Abstract
Background Reliable and affordable prognostic and predictive biomarkers for urothelial carcinoma treated with immunotherapy may allow patients' outcome stratification and drive therapeutic options. The SAUL trial investigated the safety and efficacy of atezolizumab in a real-world setting on 1004 patients with locally advanced or metastatic urothelial carcinoma who progressed to one to three prior systemic therapies. Patients and methods Using the SAUL Italian cohort of 267 patients, we investigated the prognostic role of neutrophil-to-lymphocyte ratio (NLR) and systemic immune-inflammation index (SII) and the best performing one of these in combination with programmed death-ligand 1 (PD-L1) with or without lactate dehydrogenase (LDH). Previously reported cut-offs (NLR >3 and NLR >5; SII >1375) in addition to study-defined ones derived from receiver operating characteristic (ROC) analysis were used. Results The cut-off values for NLR and SII by the ROC analysis were 3.65 (sensitivity 60.4; specificity 63.0) and 884 (sensitivity 64.4; specificity 67.5), respectively. The median overall survival (OS) was 14.7 months for NLR <3.65 [95% confidence interval (CI) 9.9-not reached (NR)] versus 6.0 months for NLR ≥3.65 (95% CI 3.9-9.4); 14.7 months for SII <884 (95% CI 10.6-NR) versus 6.0 months for SII ≥884 (95% CI 3.7-8.6). The combination of SII, PD-L1, and LDH stratified OS better than SII plus PD-L1 through better identification of patients with intermediate prognosis (77% versus 48%, respectively). Multivariate analyses confirmed significant correlations with OS and progression-free survival for both the SII + PD-L1 + LDH and SII + PD-L1 combinations. Conclusion The combination of immune-inflammatory biomarkers based on SII, PD-L1, with or without LDH is a potentially useful and easy-to-assess prognostic tool deserving validation to identify patients who may benefit from immunotherapy alone or alternative therapies. Reliable biomarkers for immunotherapy may assist in treatment decision making and clinical trial design and interpretation. Immune-inflammatory biomarkers were investigated for their prognostic role within the Italian SAUL study cohort. ROC-based cut-offs were 3.65 for NLR and 884 for SII. Both NLR and SII were prognostic with SII performing slightly better than NLR. The combination of SII, PD-L1, and LDH stratified OS better than SII + PD-L1; both were independent prognostic factors.
Collapse
Affiliation(s)
- G Fornarini
- Medical Oncology Unit 1, IRCCS Ospedale Policlinico San Martino, Genova, Italy
| | - S E Rebuzzi
- Medical Oncology Unit 1, IRCCS Ospedale Policlinico San Martino, Genova, Italy; Department of Internal Medicine and Medical Specialties, University of Genoa, Genoa, Italy
| | - G L Banna
- Department of Oncology, Portsmouth Hospitals University NHS Trust, Portsmouth, UK
| | - F Calabrò
- Medical Oncology, Azienda Ospedaliera S. Camillo-Forlanini, Rome, Italy
| | - G Scandurra
- Medical Oncology, Azienda Ospedaliera Cannizzaro di Catania, Catania, Italy
| | - U De Giorgi
- Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) - IRCCS, Meldola, Italy
| | - C Masini
- Medical Oncology, AUSL-IRCCS di Reggio Emilia, Reggio Emilia, Italy
| | - C Baldessari
- Oncology, Azienda Ospedaliero - Universitaria di Modena, Modena, Italy
| | - E Naglieri
- Division of Medical Oncology, IRCCS Istituto Tumori Bari Giovanni Paolo II - IRCCS, Bari, Italy
| | - C Caserta
- Medical Oncology Unit, Azienda Ospedaliera S. Maria, Terni, Italy
| | - S Manacorda
- Medical Oncology, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy
| | - M Maruzzo
- Medical Oncology Unit 1, Department of Oncology, Istituto Oncologico Veneto, IOV-IRCCS, Padua, Italy
| | - M Milella
- Dipartimento di Oncologia, Policlinico Universitario G.B. Rossi Borgo Roma, Verona, Italy
| | - C Buttigliero
- Medical Oncology, Università degli Studi di Torino, Turin, Italy
| | - R Tambaro
- U.O.C di Oncologia Sperimentale Uroginecologica, I.N.T. IRCCS Fondazione G. Pascale, Naples, Italy
| | - P Ermacora
- Dipartimento di Oncologia, Azienda Ospedaliero Universitaria di Udine, Udine, Italy
| | - F Morelli
- Casa Sollievo della Sofferenza, S. Giovanni Rotondo, Foggia, Italy
| | - F Nolè
- IEO, Istituto Europeo di Oncologia IRCCS, Milan, Italy
| | - C Astolfi
- Medical Affairs & Clinical Operation, Roche S.p.A., Monza, Italy
| | - C N Sternberg
- Hematology and Oncology, Englander Institute for Precision Medicine Weill Cornell Medicine, New York-Presbyterian, New York, USA.
| |
Collapse
|
8
|
Mennitto A, Verzoni E, Cognetti F, Miceli R, Milella M, Mosca A, Chiuri VE, Bearz A, Morelli F, Ortega C, Atzori F, Donini M, Claps M, Guadalupi V, Sepe P, Cappelletti V, de Braud FG, Procopio G. Radical metastasectomy followed by sorafenib versus observation in patients withclear cell renal cell carcinoma: extended follow -up of efficacy results from the randomized phase II RESORT trial. Expert Rev Clin Pharmacol 2021; 14:261-268. [PMID: 33472450 DOI: 10.1080/17512433.2021.1879639] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
Abstract
Background: The RESORT trial showed no longer relapse free survival (RFS) with sorafenib following radical metastasectomy in metastatic renal cell carcinoma. We present the updated 42-month follow-up data.Methods: The phase II RESORT trial randomized patients to sorafenib or observation within 12 weeks from surgery. RFS was the primary endpoint.Results: We analyzed 68 patients (32 in sorafenib and 36 in the observation arm), randomized between November 2012 and November 2017. Eighty-one percent in the sorafenib arm and 80% in the observation arm had one metastasis . At a median follow-up of 42 months (interquartile range 31-58), in the observation arm the median RFS was 35 months, RFS probability was 57% (95% CI 42-76%) at 24 and 44% (95% CI 30-65%) at 48 months. In the sorafenib arm, median RFS was 21 months, RFS probability was 50% (95% CI 34-71%) at 24 and 32% (95% CI 18-57%) at 48 months (p = 0.342;HR 1.35;95% CI 0.72-2.54). Forty-seven percent and 37.5% of the patients in the two arms, respectively, are disease free. The site of relapses was independent of the previous metastasectomy site.Expert commentary: Sorafenib after metastasectomy did not improve RFS, but surgery in selected patients should be considered in order to potentially improve survival.Clinical trial registration: www.clinicaltrials.gov identifier is NCT0144480.
Collapse
Affiliation(s)
- A Mennitto
- Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - E Verzoni
- Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - F Cognetti
- Medical Oncology Department, Istituto Nazionale Tumori Regina Elena, Rome, Italy
| | - R Miceli
- Department of Clinical Epidemiology and Trial Organization, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - M Milella
- Department of Medicine, Medical Oncology, University and Hospital Trust of Verona, Verona, Italy
| | - A Mosca
- Multidisciplinary Oncology Outpatient Clinic, Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy
| | - V E Chiuri
- Medical Oncology Department, Ospedale Vito Fazzi, Lecce, Italy
| | - A Bearz
- Medical Oncology Department, National Cancer Institute, Aviano, Italy
| | - F Morelli
- Medical Oncology Department, IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy
| | - C Ortega
- Department of Medical Oncology, Ospedale S. Lazzaro ASL CN2 Alba-Bra, Cuneo, Italy
| | - F Atzori
- Medical Oncology Department, University Hospital, University of Cagliari, Cagliari, Italy
| | - M Donini
- Medical Oncology Department, Ospedale di Cremona, Cremona, Italy
| | - M Claps
- Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - V Guadalupi
- Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - P Sepe
- Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - V Cappelletti
- Biomarker Unit, Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale Tumori di Milano, Milan, Italy
| | - F G de Braud
- Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.,Oncology and Hemato-Oncology Department, University of Milan, Milan, Italy
| | - G Procopio
- Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| |
Collapse
|
9
|
Morelli F, Meirelles LEDF, de Souza MVF, Mari NL, Mesquita CSS, Dartibale CB, Damke GMZF, Damke E, da Silva VRS, Souza RP, Consolaro MEL. COVID-19 Infection in the Human Reproductive Tract of Men and Nonpregnant Women. Am J Trop Med Hyg 2021; 104:814-825. [PMID: 33534765 PMCID: PMC7941816 DOI: 10.4269/ajtmh.20-1098] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/28/2020] [Accepted: 01/07/2021] [Indexed: 01/08/2023] Open
Abstract
SARS-CoV-2 is an enveloped non-segmented positive-sense RNA virus, classified as a beta coronavirus, responsible for the COVID-19 pandemic. Angiotensin-converting enzyme 2 (ACE2), reported as a SARS-CoV-2 receptor, is expressed in different human tissues (lung, intestine, and kidney) and in the testis, ovaries, uterus, and vagina. This suggests a potential risk to the human reproductive tract in COVID-19 patients. In addition, SARS-CoV-2 RNA has been detected in the blood, urine, facial/anal swabs, semen, and vaginal secretion, suggesting other potential means of transmission. However, little has been reported about SARS-CoV-2 infection in the male and nonpregnant female reproductive tracts, which may provide direct evidence on sexual transmission and fertility problems. Therefore, we focused this narrative review mainly on the distribution of ACE2 and SARS-CoV-2 positivity in the male and nonpregnant female reproductive tracts, providing an overview of the potential threat of COVID-19 to reproductive health and sexual transmission.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | - Marcia E. L. Consolaro
- Address correspondence to Marcia E. L. Consolaro, Department of Clinical Analysis and Biomedicine, Laboratory of Clinical Cytology and Semen Analysis, State University of Maringá, Av. Colombo, 5790, Zona 7, Maringá 87020-900, Brazil. E-mail:
| |
Collapse
|
10
|
Secco S, Brambillasca P, Dell’Oglio P, Barbosa F, Charalambous S, Galfano A, Alfonsi A, Morelli F, Vercelli R, Solcia M, Nichelatti M, Spinelli M, Bocciardi A, Rampoldi A. Evaluation of the efficacy of prostatic artery embolization (PAE) in patients with benign outlet obstruction (BOO) due to intravesical prostatic protrusion: clinical findings and computerized assessments of volumetric data achieved from prostatic mpMRI. EUR UROL SUPPL 2020. [DOI: 10.1016/s2666-1683(20)35433-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
11
|
Procopio G, Cognetti F, Miceli R, Milella M, Mosca A, Chiuri V, Bearz A, Morelli F, Ortega C, Atzori F, Donini M, Passalacqua R, Mennitto A, Sepe P, Martinetti A, Montone R, Apollonio G, Guadalupi V, Verzoni E, Claps M. 736P Updated data on patients (pts) with metastatic renal cell carcinoma (mRCC) treated with sorafenib (SOR) vs observation (obs) after radical metastasectomy in the RESORT trial. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.808] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
12
|
Morelli F, Souza RP, Cruz TED, Damke GMZF, Damke E, Suehiro TT, Silva VRSD, Consolaro MEL. Zika virus infection in the genital tract of non-pregnant females: a systematic review. Rev Inst Med Trop Sao Paulo 2020; 62:e16. [PMID: 32130356 PMCID: PMC7051180 DOI: 10.1590/s1678-9946202062016] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2019] [Accepted: 02/03/2020] [Indexed: 12/12/2022] Open
Abstract
This review provides a general overview on the positivity and persistence of Zika virus (ZIKV) in female genital tract (FGT) of non-pregnant women and animals, as well as in cell cultures, and its influence on FGT health. We performed a systematic review based on the PRISMA statement to identify studies focused on "Zika virus" and "non-pregnant female" in PubMed, Embase, Scopus Scholar and Web of Knowledge databases of full-text papers and abstracts published in English, with no restrictions regarding the initial date of publication, up to August 2019. Our search terms yielded 625 records, that were 108 after removal of duplicates, leaving 517 items for title and abstract reviews. Of these, 475 did not meet the inclusion criteria, leaving 42 records for full-text review and resulting in the exclusion of 6 additional records. The remaining 36 met our inclusion criteria. Variations were observed regarding the presence and persistence of ZIKV in lower and upper genital samples. However, the FGT was the place in which ZIKV RNA has been detected, sometimes for relatively long periods, even after the clearance from blood and urine. In addition to the vagina and cervix, the endometrium, uterus and ovary (oocytes and follicles) could also be involved in persistent ZIKV infections. Further prospective studies are needed to assess the effect of ZIKV on FGT health.
Collapse
Affiliation(s)
- Fabrício Morelli
- Universidade Estadual de Maringá, Departamento de Análises Clínicas e Biomedicina, Programa de Pós-Graduação em Biociências e Fisiopatologia, Maringá, Paraná, Brazil
| | - Raquel Pantarotto Souza
- Universidade Estadual de Maringá, Departamento de Análises Clínicas e Biomedicina, Programa de Pós-Graduação em Biociências e Fisiopatologia, Maringá, Paraná, Brazil
| | - Taís Elisângela da Cruz
- Universidade Estadual de Maringá, Departamento de Análises Clínicas e Biomedicina, Programa de Pós-Graduação em Biociências e Fisiopatologia, Maringá, Paraná, Brazil
| | - Gabrielle Marconi Zago Ferreira Damke
- Universidade Estadual de Maringá, Departamento de Análises Clínicas e Biomedicina, Programa de Pós-Graduação em Biociências e Fisiopatologia, Maringá, Paraná, Brazil
| | - Edilson Damke
- Universidade Estadual de Maringá, Departamento de Análises Clínicas e Biomedicina, Programa de Pós-Graduação em Biociências e Fisiopatologia, Maringá, Paraná, Brazil
| | - Tamy Tuani Suehiro
- Universidade Estadual de Maringá, Departamento de Análises Clínicas e Biomedicina, Programa de Pós-Graduação em Biociências e Fisiopatologia, Maringá, Paraná, Brazil
| | - Vânia Ramos Sela da Silva
- Universidade Estadual de Maringá, Departamento de Análises Clínicas e Biomedicina, Programa de Pós-Graduação em Biociências e Fisiopatologia, Maringá, Paraná, Brazil
| | - Marcia Edilaine Lopes Consolaro
- Universidade Estadual de Maringá, Departamento de Análises Clínicas e Biomedicina, Programa de Pós-Graduação em Biociências e Fisiopatologia, Maringá, Paraná, Brazil
| |
Collapse
|
13
|
da Cruz TE, Souza RP, Pelloso SM, Morelli F, Suehiro TT, Damke E, Bonfim-Mendonça PDS, da Silva VRS, Consolaro MEL. Case Reports: Prolonged Detection of Zika Virus RNA in Vaginal and Endocervical Samples from a Brazilian Woman, 2018. Am J Trop Med Hyg 2019; 100:183-186. [PMID: 30398145 DOI: 10.4269/ajtmh.18-0623] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
Zika virus (ZIKV) infection is an emerging public health problem, associated with increased risk for Guillain-Barré syndrome and adverse fetal outcomes, including congenital microcephaly. Zika virus sexual transmission is known, but detection of the virus in different parts of the female reproductive tract is not well established. In this case report, we describe prolonged detection of ZIKV RNA in the vaginal secretion and endocervical mucosa from a Brazilian woman convalescent to ZIKV infection. A viral load of 2 × 102 copies/mL was detected up to 31 days after symptom onset in both samples. Other biological fluids, including whole blood, plasma, serum, urine, and saliva samples, were negative for ZIKV RNA. These findings advance the understanding of ZIKV infection and provide data for additional testing strategies.
Collapse
Affiliation(s)
- Taís E da Cruz
- Department of Clinical Analysis and Biomedicine, Universidade Estadual de Maringá, Paraná, Brazil
| | - Raquel P Souza
- Department of Clinical Analysis and Biomedicine, Universidade Estadual de Maringá, Paraná, Brazil
| | - Sandra M Pelloso
- Department of Nursing, Universidade Estadual de Maringá, Paraná, Brazil
| | - Fabrício Morelli
- Department of Clinical Analysis and Biomedicine, Universidade Estadual de Maringá, Paraná, Brazil
| | - Tamy T Suehiro
- Department of Clinical Analysis and Biomedicine, Universidade Estadual de Maringá, Paraná, Brazil
| | - Edilson Damke
- Department of Clinical Analysis and Biomedicine, Universidade Estadual de Maringá, Paraná, Brazil
| | | | - Vânia R S da Silva
- Department of Clinical Analysis and Biomedicine, Universidade Estadual de Maringá, Paraná, Brazil
| | - Marcia E L Consolaro
- Department of Clinical Analysis and Biomedicine, Universidade Estadual de Maringá, Paraná, Brazil
| |
Collapse
|
14
|
Masini C, Ciammella P, Timon G, Gnoni R, De Giorgi U, Bellia S, Buti S, Salaroli F, Milella M, Mazzarotto R, Mucciarini C, Vitale M, Bruni A, Procopio G, Kinspergher S, Nole F, Morelli F, Pappagallo G, buttigliero C, Pinto C. First results of safety profile of nivolumab (NIVO) in combination with stereotactic body radiotherapy (SBRT) in II and III line of patients (pts) with metastatic renal cell carcinoma (mRCC) in NIVES study. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz249.057] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
15
|
Bossi P, Merlano M, Ghi M, Rinaldi G, Caponigro F, Morelli F, Airoldi M, Farnesi A, Cassano A, Ferrari D, Mirabile A, Tosoni A, Galizia D, Moretti G, Sponghini A, Calareso G, Vingiani A, Perrone F, Falletta A, Licitra L. A single-arm, open-label, multicenter, phase IIIb clinical trial with nivolumab in subjects with recurrent or metastatic platinum-refractory squamous cell carcinoma of the head and neck. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz252.032] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
16
|
Suzuki SML, Morelli F, Negri M, Bonfim-Mendonça P, Kioshima ÉS, Salci T, Voidaleski MF, Vicente VA, Svidzinski T. FATAL cryptococcal meningitis in a child with hyper-immunoglobulin M syndrome, with an emphasis on the agent. J Mycol Med 2019; 29:273-277. [PMID: 31409527 DOI: 10.1016/j.mycmed.2019.07.002] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2018] [Revised: 06/22/2019] [Accepted: 07/03/2019] [Indexed: 10/26/2022]
Abstract
Following a fatal case of Cryptococcus neoformans meningitis in a child with X-linked hyper-immunoglobulin M syndrome (XHIGM), we evaluated the fungal isolate in an experimental infection in a mouse model with respect to microbiology, epidemiology, virulence and response to therapy. The minimum inhibitory concentrations for antifungals in the susceptibility test were 0.5mg/L for amphotericin B, 4.0mg/L for fluconazole and 0.12mg/L for voriconazole. Evaluation of pathogenicity by means of an experimental infection in BALB/c mice showed that fungus isolated from the blood and cerebrospinal fluid of the child was able to disseminate, reaching the spleen, lungs and brain, where it caused significant macroscopic alterations in the size and texture of each organ. Treatment of infected mice with amphotericin B reduced the fungal load in the spleen and lungs, but not in the brain.
Collapse
Affiliation(s)
- S M L Suzuki
- Section of Medical Mycology, Universidade Estadual de Maringá, Maringá, Brazil
| | - F Morelli
- Section of Medical Mycology, Universidade Estadual de Maringá, Maringá, Brazil
| | - M Negri
- Section of Medical Mycology, Universidade Estadual de Maringá, Maringá, Brazil
| | - P Bonfim-Mendonça
- Section of Medical Mycology, Universidade Estadual de Maringá, Maringá, Brazil
| | - É S Kioshima
- Section of Medical Mycology, Universidade Estadual de Maringá, Maringá, Brazil
| | - T Salci
- Section of Medical Mycology, Universidade Estadual de Maringá, Maringá, Brazil; Department of Pharmacy, Faculdade Integrado, Campo Mourão, Paraná, Brazil
| | - M F Voidaleski
- Microbiology, Parasitology and Pathology Post-Graduation Program, Department of Pathology, Universidade Federal do Paraná, Curitiba, Paraná, Brazil
| | - V A Vicente
- Microbiology, Parasitology and Pathology Post-Graduation Program, Department of Pathology, Universidade Federal do Paraná, Curitiba, Paraná, Brazil
| | - T Svidzinski
- Section of Medical Mycology, Universidade Estadual de Maringá, Maringá, Brazil.
| |
Collapse
|
17
|
Procopio G, Cognetti F, Miceli R, Milella M, Mosca A, Chiuri V, Bearz A, Morelli F, Ortega C, Atzori F, Passalacqua R, Ratta R, de Braud F, Cappelletti V, Verzoni E. Subgroups analysis and circulating biomarkers evaluation of RESORT trial: A randomized phase II study in metastatic renal cell carcinoma (mRCC) patients (pts) to evaluate the efficacy of sorafenib after metastasectomy. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy283.089] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
18
|
Ghi MG, Paccagnella A, Ferrari D, Foa P, Alterio D, Codecà C, Nolè F, Verri E, Orecchia R, Morelli F, Parisi S, Mastromauro C, Mione CA, Rossetto C, Polsinelli M, Koussis H, Loreggian L, Bonetti A, Campostrini F, Azzarello G, D'Ambrosio C, Bertoni F, Casanova C, Emiliani E, Guaraldi M, Bunkheila F, Bidoli P, Niespolo RM, Gava A, Massa E, Frattegiani A, Valduga F, Pieri G, Cipani T, Da Corte D, Chiappa F, Rulli E. Induction TPF followed by concomitant treatment versus concomitant treatment alone in locally advanced head and neck cancer. A phase II-III trial. Ann Oncol 2018; 28:2206-2212. [PMID: 28911070 DOI: 10.1093/annonc/mdx299] [Citation(s) in RCA: 101] [Impact Index Per Article: 16.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Background Platinum-based chemoradiation (CCRT) is the standard treatment for Locally Advanced Head and Neck Squamous-Cell Carcinoma (LAHNSCC). Cetuximab/RT (CET/RT) is an alternative treatment option to CCRT. The efficacy of induction chemotherapy (IC) followed by chemoradiation compared to chemoradiation alone has not been demonstrated in randomized clinical trials. The goals of this phase II-III trial were to assess: (i) the overall survival (OS) of IC versus no-induction (no-IC) and (ii) the Grade 3-4 in-field mucosal toxicity of CCRT versus CET/RT. The present paper focuses on the analysis of efficacy. Materials and methods Patients with LAHNSCC were randomized to receive concomitant treatment alone [CCRT (Arm A1) or CET/RT (Arm A2)], or three cycles of induction docetaxel/cisplatin/5 fluorouracil (TPF) followed by CCRT (Arm B1) or followed by CET/RT (Arm B2). The superiority hypothesis of OS comparison of IC versus no-IC (Arms B1 + B2 versus A1 + A2) required 204 deaths to detect an absolute 3-year OS difference of 12% (HR 0.675, with 80% power at two-sided 5% significance level). Results 414 out of 421 patients were finally analyzed: 206 in the IC and 208 in the no-IC arm. Six patients were excluded because of major violation and one because of metastatic disease at diagnosis. With a median follow-up of 44.8 months, OS was significantly higher in the IC arm (HR 0.74; 95% CI 0.56-0.97; P = 0.031). Complete Responses (P = 0.0028), Progression Free Survival (P = 0.013) and the Loco-regional Control (P = 0.036) were also significantly higher in the IC arm. Compliance to concomitant treatments was not affected by induction TPF. Conclusions IC followed by concomitant treatment improved the outcome of patients with LAHNSCC without compromising compliance to the concomitant treatments. The degree of the benefit of IC could be different according to the type of the subsequent concomitant strategy. Clinical Trial Number NCT01086826, www.clinicaltrials.gov.
Collapse
Affiliation(s)
- M G Ghi
- Medical Oncology Department, Ospedale dell'Angelo, Venezia
| | - A Paccagnella
- Medical Oncology Department, Ospedale dell'Angelo, Venezia
| | - D Ferrari
- Medical Oncology Unit, Ospedale San Paolo, Milano
| | - P Foa
- Medical Oncology Unit, Ospedale San Paolo, Milano
| | | | - C Codecà
- Medical Oncology Unit, Ospedale San Paolo, Milano
| | - F Nolè
- Unit of Urogenital and Head and Neck Oncology, Istituto Europeo di Oncologia, Milano
| | - E Verri
- Unit of Urogenital and Head and Neck Oncology, Istituto Europeo di Oncologia, Milano
| | | | | | - S Parisi
- U.O.C. Radiation Oncology, IRCCS Casa Sollievo della Sofferenza, San Giovanni, Rotondo
| | - C Mastromauro
- Medical Oncology Department, Ospedale dell'Angelo, Venezia
| | - C A Mione
- Radiotherapy Department, Ospedale SS Giovanni e Paolo, Venezia
| | | | - M Polsinelli
- S.O.C. Radiation Oncology, Azienda Ospedaliero-Universitaria S.Maria della Misericordia, Udine
| | - H Koussis
- Medical Oncology Department 2, Istituto Oncologico Veneto- IRCCS, Padova
| | - L Loreggian
- Radiotherapy Department, Istituto Oncologico Veneto - IRCCS, Padova
| | - A Bonetti
- Medical Oncology Department, Ospedale Mater Salutis, Legnago
| | - F Campostrini
- Radiotherapy Department, Ospedale Mater Salutis, Legnago
| | - G Azzarello
- Oncology Unit, Department of Internal Medical Sciences, Mirano
| | | | - F Bertoni
- Radiotherapy Department, Azienda Ospedaliero Universitaria, Modena
| | | | - E Emiliani
- Radiotherapy Department, Azienda USL, Ravenna
| | - M Guaraldi
- Medical Oncology Department, Policlinico Sant'Orsola-Malpighi, Bologna
| | - F Bunkheila
- Radiotherapy Department, Policlinico Sant'Orsola-Malpighi, Bologna
| | - P Bidoli
- Medical Oncology Department, Ospedale San Gerardo, Monza
| | - R M Niespolo
- Radiotherapy Department, Ospedale San Gerardo, Monza, Ospedale San Gerardo, Monza
| | - A Gava
- Radiotherapy Department, Ospedale Ca' Foncello, Treviso
| | - E Massa
- Department of Medical Science, Università degli Studi di Cagliari, Cagliari
| | - A Frattegiani
- Radiation Oncology Department, Ospedale S. Maria della Misericordia, Perugia
| | - F Valduga
- Medical Oncology Department, Ospedale S. Chiara, Trento
| | - G Pieri
- Medical Oncology Department, AO Triestina, Trieste
| | - T Cipani
- Niguarda Cancer Center, Ospedale Niguarda Cà Granda, Milano
| | - D Da Corte
- Oncology Department, Ospedale S. Martino, Belluno
| | - F Chiappa
- Laboratory of Clinical Research, Istituto di Ricerche Farmacologiche "Mario Negri," Milano, Italy
| | - E Rulli
- Laboratory of Clinical Research, Istituto di Ricerche Farmacologiche "Mario Negri," Milano, Italy
| | | |
Collapse
|
19
|
Valbonesi M, Florio G, Ruzzenenti M, Bo A, Bruni R, Giannini G, Morelli F. Multicomponent Collection (MCC) with the Latest Hemapheresis Apparatuses. Int J Artif Organs 2018. [DOI: 10.1177/039139889902200710] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Affiliation(s)
- M. Valbonesi
- Immunohematology Service, San Martino University Hospital, Genova - Italy
| | - G. Florio
- Immunohematology Service, San Martino University Hospital, Genova - Italy
| | - M.R. Ruzzenenti
- Immunohematology Service, San Martino University Hospital, Genova - Italy
| | - A. Bo
- Immunohematology Service, San Martino University Hospital, Genova - Italy
| | - R. Bruni
- Immunohematology Service, San Martino University Hospital, Genova - Italy
| | - G. Giannini
- Immunohematology Service, San Martino University Hospital, Genova - Italy
| | - F. Morelli
- Immunohematology Service, San Martino University Hospital, Genova - Italy
| |
Collapse
|
20
|
Valbonesi M, Florio G, Frisoni R, Morelli F. Preparation and Storage in Plasma-Lyte a of Platelets Collected with the Cell Separator CS3000 plus Equipped with the PLT30-Separation and TNX6 Collection Chambers. Int J Artif Organs 2018. [DOI: 10.1177/039139889501800109] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Affiliation(s)
- M. Valbonesi
- Immunohematology Services, Regional Reference Center, San Martino University Hospital, Genova - Italy
| | - G. Florio
- Immunohematology Services, Regional Reference Center, San Martino University Hospital, Genova - Italy
| | - R. Frisoni
- Immunohematology Services, Regional Reference Center, San Martino University Hospital, Genova - Italy
| | - F. Morelli
- Immunohematology Services, Regional Reference Center, San Martino University Hospital, Genova - Italy
| |
Collapse
|
21
|
Abstract
The extensive application of IOBS has permitted a great reduction in the use of homoglous transfusion which presently represents the largest field of application of autologous systems. In cardiac and vascular surgery, IOBS is particularly useful to the goal of preventing the transmission of viral disorders and other adverse effects related to homologous transfusions. The apparatuses for IOBS may also be used to perform hemodilution and sequestration of a desired amount of platelet rich plasma. The appropriate usage of drugs in perioperative period and the promotion of hemostasis with IOBS are important costituents for the correct transfusional management of the patient. The feasibility and safety of IOBS is known and in expert hands it is an optimal method for the transfusional treatment of surgical patients
Collapse
Affiliation(s)
- M. Valbonesi
- Immunohematology Services, San Martino University Hospital, Genova - Italy
| | - P. Carlier
- Immunohematology Services, San Martino University Hospital, Genova - Italy
| | - G. Florio
- Immunohematology Services, San Martino University Hospital, Genova - Italy
| | - F. Morelli
- Immunohematology Services, San Martino University Hospital, Genova - Italy
| | - M.R. Ruzzenenti
- Immunohematology Services, San Martino University Hospital, Genova - Italy
| |
Collapse
|
22
|
Abstract
Patients with extremely high triglyceride levels and associated lipemia are at high risk for acute pancreatitis. Two factors can increase triglyceride-rich lipoproteins; one is overproduction and other is a defect in clearance. Either mechanism can cause hypertriglyceridemia and both may exist simultaneously. Causes can be either primary or secondary. Plasmapheresis is efficacious for severe hypertryceridemia in patients who have not responded to previous therapies. We have treated 15 cases of hypertrygliceridemia complicating the course of patients receiving Cyclosporin A after bone marrow transplantation. Five patients were treated with plasmapheresis, the other ten with cascade filtration. The removal rate for triglycerides was 58.0% for patients treated by cascade filtration and 63.5% for patients treated by plasmapheresis. The removal rates for triglycerides were low possibly as a consequence of early saturation of the filter.
Collapse
Affiliation(s)
- G Giannini
- Department of Immunohematology, Immunohematology Services, S. Martino University Hospital, Genova--Italy.
| | | | | | | | | | | | | |
Collapse
|
23
|
Affiliation(s)
- F. Morelli
- Faculty of Environmental Sciences; Department of Applied Geoinformatics and Spatial Planning; Czech University of Life Sciences Prague; Prague Czech Republic
| |
Collapse
|
24
|
Morelli F, Ferarrese L, Munhoz C, Alberton O. Antimicrobial activity of essential oil and growth of Ocimum basilicum (L.) inoculated with mycorrhiza and humic substances applied to soil. Genet Mol Res 2017. [DOI: 10.4238/gmr16039710] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
25
|
Houédé N, Locker G, Lucas C, Parra HS, Basso U, Spaeth D, Tambaro R, Basterretxea L, Morelli F, Theodore C, Lusuardi L, Lainez N, Guillot A, Tonini G, Bielle J, Del Muro XG. Epicure: a European epidemiological study of patients with an advanced or metastatic Urothelial Carcinoma (UC) having progressed to a platinum-based chemotherapy. BMC Cancer 2016; 16:752. [PMID: 27664126 PMCID: PMC5035464 DOI: 10.1186/s12885-016-2782-3] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2016] [Accepted: 09/14/2016] [Indexed: 01/31/2023] Open
Abstract
Background Platinum-based systemic chemotherapy is considered the backbone for management of advanced urothelial carcinomas. However there is a lack of real world data on the use of such chemotherapy regimens, on patient profiles and on management after treatment failure. Methods Fifty-one randomly selected physicians from 4 European countries registered 218 consecutive patients in progression or relapse following a first platinum-based chemotherapy. Patient characteristics, tumor history and treatment regimens, as well as the considerations of physicians on the management of urothelial carcinoma were recorded. Results A systemic platinum-based regimen had been administered as the initial chemotherapy in 216 patients: 15 in the neoadjuvant setting, 61 in adjuvant therapy conditions, 137 in first-line advanced setting and 3 in other conditions. Of these patients, 76 (35 %) were initially considered as cisplatin-unfit, mainly because of renal impairment (52 patients). After platinum failure, renal impairment was observed in 44 % of patients, ECOG Performance Status ≥ 2 in 17 %, hemoglobinemia < 10 g/dL in 16 %, hepatic metastases in 13 %. 80 % of these patients received further anticancer therapy. Immediately after failure of adjuvant/neoadjuvant chemotherapy, most subsequent anticancer treatments were chemotherapy doublets (35/58), whereas after therapy failure in the advanced setting most patients receiving further anticancer drugs were treated with a single agent (80/114). After first progression to chemotherapy, treatment decisions were mainly driven by Performance Status and prior response to chemotherapy (>30 % patients). The most frequent all-settings second anticancer therapy regimen was vinflunine (70 % of single-agent and 42 % of all subsequent treatments), the main reasons evoked by physicians (>1 out of 4) being survival benefit, safety and phase III evidence. Conclusion In this daily practice experience, a majority of patients with urothelial carcinoma previously treated with a platinum-based therapy received a second chemotherapy regimen, most often a single agent after an initial chemotherapy in the advanced setting and preferably a cytotoxic combination after a neoadjuvant or adjuvant chemotherapy. Performance Status and prior response to chemotherapy were the main drivers of further treatment decisions.
Collapse
Affiliation(s)
- N Houédé
- Institut de Cancérologie du Gard - CHU Caremeau, 30029, Nîmes, Cedex 9, France.
| | - G Locker
- Department of Internal Medicine I, Währinger Gürtel.18-20, 1090, Vienne, Austria
| | - C Lucas
- Institut de Recherche Pierre Fabre, 45 place Abel Gance, 92100, Boulogne-Billancourt, France
| | - H Soto Parra
- Oncologia Medica, P.O Gaspare Rodolico, Via Santa Sofia 78, 95123, Catania, Italy
| | - U Basso
- Istituto Oncologico Veneto IOV-IRCCS, Dipartmento di Oncologia Clinica e Sperimentale, Oncologia Medica 1, via Gattamelata 64, 35128, Padova, Italy
| | - D Spaeth
- Centre d'Oncologie de Gentilly, 2 rue Marie Marvingt, 54100, Nancy, France
| | - R Tambaro
- Istituto Nazionale Tumori IRCCS Fondazione Pascale, Via Mariano Semmola, 80131, Napoli, Italy
| | - L Basterretxea
- Hospital Universitario Donostia, Begiristain Doktorea Pasealekua 117-20080, Donostia, Gipuzkoa - San Sebastián, Spain
| | - F Morelli
- Fondazione Casa Sollievo della Sofferenza Oncologia, Viale Cappuccini 1, San Giovanni Rotondo, Foggia, Italy
| | - C Theodore
- Hopital Foch, 40 rue Worth, 92150, Suresnes, France
| | - L Lusuardi
- Reparto di Urologia - Ospedale di Bressanone, Via Dante 51, 39042, Bressanone, Italy
| | - N Lainez
- Hospital de Navarra - Virgen del Camino, Oncología Médica, Calle de Irunlarrea, 4 planta baja, 31008, Pamplona, Spain
| | - A Guillot
- Institut de cancérologie de la Loire, 108 bis avenue Albert Raimond, 42271, Saint Priest en Jarez, Cedex, France
| | - G Tonini
- Policlinico Universitario Campus Bio-medico Oncologia Medica, Via Alvaro del Portillo 200, 00128, Roma, Italy
| | - J Bielle
- Institut de Recherche Pierre Fabre, 45 place Abel Gance, 92100, Boulogne-Billancourt, France
| | - X Garcia Del Muro
- ICO L'Hospitalet, Avinguda Granvia, 199-203, 08907, L'Hospitalet de Llobregat, Barcelona, Spain
| |
Collapse
|
26
|
Bersanelli M, Maines F, Facchini G, Gelsomino F, Zustovich F, Santoni M, Verri E, De Giorgi U, Masini C, Morelli F, Vitale M, Sava T, Prati G, Librici C, Fraccon A, Fornarini G, Maruzzo M, Leonardi F, Caffo O, Buti S. First-line PAzopanib in NOn-clear cell Renal cArcinoMA: the Italian retrospective multicenter PANORAMA study. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw334.10] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
27
|
Bracarda S, Iacovelli R, Boni L, Rizzo M, Derosa L, Rossi M, Galli L, Procopio G, Sisani M, Longo F, Santoni M, Morelli F, Di Lorenzo G, Altavilla A, Porta C, Camerini A, Escudier B. Correction to: Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis. Ann Oncol 2016; 27:366. [DOI: 10.1093/annonc/mdv589] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
28
|
Houede N, Locker G, Lucas C, Parra HS, Basso U, Spaeth D, Tambaro R, Basterretxea L, Morelli F, Theodore C, Lusuardi L, Lainez N, Guillot A, Tonini G, Burillon J, Del Muro XG. 2627 Characteristics and treatments patterns of patients with an advanced or metastatic urothelial carcinoma (UC) after failure of a platinum-based chemotherapy (CT): Results of the European observational study EPICURE. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)31444-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
29
|
Bracarda S, Iacovelli R, Boni L, Rizzo M, Derosa L, Rossi M, Galli L, Procopio G, Sisani M, Longo F, Santoni M, Morelli F, Di Lorenzo G, Altavilla A, Porta C, Camerini A, Escudier B, Ricotta R, Gasparro D, Sabbatini R, Ceresoli GL, Mosca A, Santini D, Caserta C, Cavanna L, Massari F, Sava T, Boni C, Verzoni E, Cartenì G, Hamzaj A. Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis. Ann Oncol 2015. [PMID: 26216384 DOI: 10.1093/annonc/mdv315] [Citation(s) in RCA: 69] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022] Open
Abstract
BACKGROUND First-line sunitinib is recommended in metastatic renal cell carcinoma (mRCC), but it is frequently associated with relevant toxicities and subsequent dose reductions. Alternative schedules, such as 2-week-on treatment and 1-week-off (2/1 schedule), might improve tolerability. We evaluated the safety and outcomes of this schedule in a large multicenter analysis. PATIENTS AND METHODS Retrospective, multicenter analysis of mRCC patients treated with first-line sunitinib on a 2/1 schedule. Data of 249 patients were reviewed: 208 cases who started sunitinib on the 4/2 schedule (full dosage: 188/208, 90.4%) and thereafter switched to the 2/1 schedule for toxicity (group 4/2 → 2/1) and 41 patients who started first-line sunitinib with the 2/1 schedule because of suboptimal clinical conditions (group 2/1). A total of 211 consecutive patients treated with the 4/2 schedule in another institution served as external controls. Safety was the primary end point. Treatment duration (TD), progression-free survival (PFS) and overall survival (OS) were also analyzed. RESULTS In group 4/2 → 2/1, the overall incidence of grade ≥ 3 toxicities was significantly reduced (from 45.7% to 8.2%, P < 0.001) after the switch to 2/1 schedule. This advantage was maintained also in the 106/188 cases (56.4%) who maintained the full dosage. Fatigue, hypertension, hand-foot syndrome and thrombocytopenia were less frequent. The incidence of grade ≥ 3 adverse events in the negatively selected group 2/1 (only 73.2% starting at full dose) was 26.8%, similar to what observed in the external control group (29.4%). Median TD was 28.2 months in the 4/2 → 2/1 group (total time spent with both schedules), 7.8 months in the 2/1 group and 9.7 months in external controls. Median PFS was 30.2, 10.4 and 9.7 months, respectively. Median OS was not reached, 23.2 and 27.8 months, respectively. CONCLUSIONS mRCC patients who moved to a modified 2/1 schedule of sunitinib experience an improved safety profile compared with that observed during the initial 4/2 schedule.
Collapse
Affiliation(s)
- S Bracarda
- Ospedale San Donato USL8, Istituto Toscano Tumori (ITT), Arezzo
| | | | - L Boni
- Clinical Trials Coordinating Center, AOU Careggi, Istituto Toscano Tumori, Florence
| | - M Rizzo
- Medical Oncology; AORN Cardarelli, Napoli, Italy
| | - L Derosa
- Institut Gustave Roussy/Medical Oncology Department, Paris, France
| | - M Rossi
- Medical Oncology, Ospedale Santa Maria della Misericordia, Perugia
| | - L Galli
- Polo Oncologico AOU Pisana, Pisa
| | | | - M Sisani
- Ospedale San Donato USL8, Istituto Toscano Tumori (ITT), Arezzo
| | - F Longo
- Medical Oncology A, Policlinico Umberto I°, Roma
| | - M Santoni
- Medical Oncology, Polytechnic University of the Marche Region, Ancona
| | - F Morelli
- Medical Oncology, IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo
| | - G Di Lorenzo
- Genitourinary Cancers Section, AOU Federico II, Napoli
| | - A Altavilla
- Medical Oncology B, Policlinico Umberto I°, Roma
| | | | - A Camerini
- U.O. Oncologia Medica, Ospedale Versilia, Az. USL12, Lido Di Camaiore, Italy
| | - B Escudier
- Institut Gustave Roussy/Medical Oncology Department, Paris, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
30
|
Morelli F, Smeets L, Hobijn M, Boom H. Melioidosis and renal failure in a Dutch man after a trip to Gambia. Neth J Med 2015; 73:296-298. [PMID: 26228196] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Abstract
Melioidosis is due to Burkholderia pseudomallei and is known to be endemic in South-East Asia, while epidemiology of disease in Sub-Saharan Africa is still unclear. Prompt recognition of infection is crucial for adequate antibiotic treatment. Infection can lead to visceral abcesses and awareness of this complication is important for proper management.
Collapse
Affiliation(s)
- F Morelli
- Department of Internal Medicine, Reinier de Graaf Gasthuis, Delft, the Netherlands
| | | | | | | |
Collapse
|
31
|
Morelli F, Mróz E, Pruscini F, Santolini R, Goławski A, Tryjanowski P. Habitat structure, breeding stage and sex affect hunting success of breeding Red-backed Shrike ( Lanius collurio). ETHOL ECOL EVOL 2015. [DOI: 10.1080/03949370.2015.1022907] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
32
|
Ghi CM, Paccagnella A, Ferrari D, Foa P, Cossu Rocca M, Verri E, Morelli F, Azzarello G, D'Ambrosio C, Casanova C, Guaraldi M, Massa E, Rossetto C, Bonetti A, Siena S, Frattegiani A, Koussis H, Pieri G, Gava A, Floriani I. OC-006: Concomitant treatment (CRT or cetuximab/RT) with or without induction TPF in Locally Advanced head and neck. Radiother Oncol 2015. [DOI: 10.1016/s0167-8140(15)34766-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
33
|
Morelli F, Girardello M. Buntings (Emberizidae) as indicators of HNV of farmlands: a case of study in Central Italy. ETHOL ECOL EVOL 2014. [DOI: 10.1080/03949370.2013.852140] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
34
|
Morelli F, Tha-In T, Veldt B. A young man with intermittent abdominal pain and anaemia: a peculiar finding. Neth J Med 2014; 72:430-434. [PMID: 25387557] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Affiliation(s)
- F Morelli
- Department of Internal Medicine, Reinier de Graaf Hospital, Delft, Zuid-Holland, the Netherlands
| | | | | |
Collapse
|
35
|
Caffo O, De Giorgi U, Fratino L, Facchini G, Basso U, Alesini D, Gasparro D, Ortega C, Tucci M, Verderame F, Campadelli E, Re GL, Sabbatini R, Donini M, Procopio G, Sartori D, Zucali P, Carrozza F, D'Angelo A, Morelli F. Activity of Sequential New Drugs (Nds) Post-Docetaxel (Doc) Failure, in Metastatic Castration-Resistant Prostate Cancer (Mcrpc) Patients (Pts). Update from a Multicenter Italian Experience. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu336.38] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
36
|
Belvisi V, Del Borgo C, Morelli F, Marocco R, Tieghi T, Fabietti P, Vetica A, Lichtner M, Mastroianni C. Late onset invasive pneumococcal disease in a liver transplanted patient: beyond the Austrian syndrome. Transpl Infect Dis 2013; 15:E111-4. [DOI: 10.1111/tid.12083] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2012] [Revised: 12/08/2012] [Accepted: 01/16/2013] [Indexed: 01/02/2023]
Affiliation(s)
- V. Belvisi
- Infectious Disease Unit; SM Goretti Hospital; Fondazione Eleonora Lorillard Spencer Cenci; Sapienza University; Latina; Italy
| | - C. Del Borgo
- Infectious Disease Unit; SM Goretti Hospital; Fondazione Eleonora Lorillard Spencer Cenci; Sapienza University; Latina; Italy
| | - F. Morelli
- Infectious Disease Unit; SM Goretti Hospital; Fondazione Eleonora Lorillard Spencer Cenci; Sapienza University; Latina; Italy
| | - R. Marocco
- Infectious Disease Unit; SM Goretti Hospital; Fondazione Eleonora Lorillard Spencer Cenci; Sapienza University; Latina; Italy
| | - T. Tieghi
- Infectious Disease Unit; SM Goretti Hospital; Fondazione Eleonora Lorillard Spencer Cenci; Sapienza University; Latina; Italy
| | - P. Fabietti
- Infectious Disease Unit; SM Goretti Hospital; Fondazione Eleonora Lorillard Spencer Cenci; Sapienza University; Latina; Italy
| | - A. Vetica
- Infectious Disease Unit; SM Goretti Hospital; Fondazione Eleonora Lorillard Spencer Cenci; Sapienza University; Latina; Italy
| | - M. Lichtner
- Infectious Disease Unit; SM Goretti Hospital; Fondazione Eleonora Lorillard Spencer Cenci; Sapienza University; Latina; Italy
| | - C.M. Mastroianni
- Infectious Disease Unit; SM Goretti Hospital; Fondazione Eleonora Lorillard Spencer Cenci; Sapienza University; Latina; Italy
| |
Collapse
|
37
|
Ghi M, Paccagnella A, Ferrari D, Rocca MC, Verri E, Morelli F, Azzarello G, D'Ambrosio C, Casanova C, Floriani I. Concomitant Chemoradiotherapy (CT/RT) or CETUXIMAB/RT (CET/RT) with or Without Induction Docetaxel/Cisplatin/5-Fluorouracil (TPF) in Locally Advanced Head and Neck Cancer (LASCCHN). Preliminary Toxicity Results of a Randomized, 2x2 Factorial, Phase II-III Study. (NCT01086826). Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)33614-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
38
|
Morelli F, Santolini R, Sisti D. Breeding habitat of red-backed shrikeLanius collurioon farmland hilly areas of Central Italy: is functional heterogeneity one important key? ETHOL ECOL EVOL 2012. [DOI: 10.1080/03949370.2011.635696] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
39
|
Hernandez-Enriquez O, Alvarez R, Morelli F, Bastida F, Camacho D, Menendez J. Low-impact chemical weed control techniques in UNESCO World Heritage Sites of Cuba. Commun Agric Appl Biol Sci 2012; 77:387-393. [PMID: 23878993] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/02/2023]
Abstract
Dichrostachys cinerea is a thorny, acacia-like, fast-growing woody bush which invades fields, wasteland, road sides and other disturbed areas. This gregarious species has become a very aggressive invasive weed in Cuba, where no native predators or pathogens are found. It often encroaches in fallows, overgrazed areas and mismanaged veld. D. cinerea is a very difficult weed to eliminate because of its active suckering, and is liable to produce dense thickets which are quite impenetrable on account of the density and abundance of its long, stiff, sharp thorns. In the Valle de los Ingenios area (Cuba Central), the tree is unchecked and forms veritable forests in areas on which cane growing has been discontinued. Physical management by cutting and burning the plants is not a very efficient control method, since the seeds survive in the soil, and they grow very fast. Therefore, chemical methods via the use of herbicides are often necessary to eradicate this weed. A preliminary study using glyphosate and auxin-like herbicides (2,4-D + picloram, MCPA, and MCPA + 2,4-D) plus adjuvants has been carried out in order to elucidate the best mixtures rendering maximum weed control with minimum herbicide rate and environmental stress. None of the herbicides used except glyphosate and 2,4-D + picloram showed acceptable mortality rates (75-80%) at the recommended doses tested. In the failed herbicide treatments, only the use of double herbicide rates succeeded in controlling marabou. The herbicide mixture of 2,4-D + picloram formulated with either a non-ionic surfactant or a mixture of fatty acid esters was the best option to control D. cinerea in terms of maximum effectiveness and minimum environmental stress, as the reduction in active ingredients applied to the environment was x3 in these two adjuvant-amended formulations compared to 2,4-D + picloram alone.
Collapse
Affiliation(s)
- O Hernandez-Enriquez
- Facultad Agropecuaria de Montaña del Escambray, Universidad de Sancti Spiritus, Cuba
| | | | | | | | | | | |
Collapse
|
40
|
Bachner M, Loriot Y, Gross-Goupil M, Zucali PA, Horwich A, Germa-Lluch JR, Kollmannsberger C, Stoiber F, Fléchon A, Oechsle K, Gillessen S, Oldenburg J, Cohn-Cedermark G, Daugaard G, Morelli F, Sella A, Harland S, Kerst M, Gampe J, Dittrich C, Fizazi K, De Santis M. 2-¹⁸fluoro-deoxy-D-glucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residual lesions: a retrospective validation of the SEMPET trial. Ann Oncol 2012; 23:59-64. [PMID: 21460378 DOI: 10.1093/annonc/mdr052] [Citation(s) in RCA: 94] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND 2-¹⁸fluoro-deoxy-D-glucose positron emission tomography (FDG-PET) has been recommended in international guidelines in the evaluation of postchemotherapy seminoma residuals. Our trial was designed to validate these recommendations in a larger group of patients. PATIENTS AND METHODS FDG-PET studies in patients with metastatic seminoma and residual masses after platinum-containing chemotherapy were correlated with either the histology of the resected lesion(s) or the clinical outcome. RESULTS One hundred and seventy seven FDG-PET results were contributed. Of 127 eligible PET studies, 69% were true negative, 11% true positive, 6% false negative, and 15% false positive. We compared PET scans carried out before and after a cut-off level of 6 weeks after the end of the last chemotherapy cycle. PET sensitivity, specificity, negative predictive value (NPV), and positive predictive value were 50%, 77%, 91%, and 25%, respectively, before the cut-off and 82%, 90%, 95%, and 69% after the cut-off. PET accuracy significantly improved from 73% before to 88% after the cut-off (P=0.032). CONCLUSION Our study confirms the high specificity, sensitivity, and NPV of FDG-PET for evaluating postchemotherapy seminoma residuals. When carried out at an adequate time point, FDG-PET remains a valuable tool for clinical decision-making in this clinical setting and spares patients unnecessary therapy.
Collapse
Affiliation(s)
- M Bachner
- ACR-ITR VIEnna/CEADDP, LBI-ACR VIEnna, and KFJ-Spital, Vienna, Austria
| | - Y Loriot
- Institut Gustave Roussy, Villejuif, France
| | | | - P A Zucali
- Istituto Clinico Humanitas IRCCS, Rozzano (Milan), Italian Germ Cell Cancer Group
| | - A Horwich
- The Royal Marsden Hospital, London and Surrey, UK
| | | | | | - F Stoiber
- Krankenhaus der Barmherzigen Schwestern, Linz, Austria
| | | | - K Oechsle
- Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany
| | - S Gillessen
- Kantonsspital St. Gallen, St. Gallen, Switzerland
| | | | - G Cohn-Cedermark
- Department of Oncology-Pathology, Karolinska Institute and University Hospital, Stockholm, Sweden
| | - G Daugaard
- Department of Oncology, 5073 Rigshospitalet, Copenhagen, Denmark
| | - F Morelli
- Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy
| | - A Sella
- Assaf Harofeh Medical Center, Zerifin, Israel
| | - S Harland
- University College Hospital London, London, UK
| | - M Kerst
- The Netherlands Cancer Institute, Amsterdam, The Netherlands
| | - J Gampe
- Max Planck Institute for Demographic Research, Rostock, Germany
| | - C Dittrich
- ACR-ITR VIEnna/CEADDP, LBI-ACR VIEnna, and KFJ-Spital, Vienna, Austria
| | - K Fizazi
- Institut Gustave Roussy, Villejuif, France
| | - M De Santis
- ACR-ITR VIEnna/CEADDP, LBI-ACR VIEnna, and KFJ-Spital, Vienna, Austria.
| |
Collapse
|
41
|
Morelli F, Troiano M, Mastrodonato N, Di Maggio G, Nanni L, Lombardi L, Parisi S, Di Sebastiano P, Maiello E. 10 CHEMORADIATION THERAPY FOR CARCINOMA OF THE ANAL CANAL. Cancer Treat Rev 2010. [DOI: 10.1016/s0305-7372(10)70036-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
42
|
Lombardi L, Morelli F, Cinieri S, Santini D, Silvestris N, Fazio N, Orlando L, Tonini G, Colucci G, Maiello E. Adjuvant colon cancer chemotherapy: where we are and where we'll go. Cancer Treat Rev 2010; 36 Suppl 3:S34-41. [PMID: 21129608 DOI: 10.1016/s0305-7372(10)70018-9] [Citation(s) in RCA: 62] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
Many patients with early-stage colon cancer are cured with surgery alone, even if the standard of care remains an uniform approach to adjuvant chemotherapy based primarily on tumour stage. Consequently, it is important to individualize decision-making in this subset of patients with the aim to identify potential prognostic and predictive markers in colon cancer. While 5-fluorouracil, leucovorin, and oxaliplatin are widely known as gold treatment in the post-operative of stage III, well-validated molecular markers might help define which patients with stage II disease are likely to benefit from adjuvant therapy as well. Herein we review the use of adjuvant chemotherapy in colon cancer and analyzed the date on the clinical development of molecular markers to individualize another therapeutic approach in colon cancer.
Collapse
Affiliation(s)
- L Lombardi
- Medical Oncology Unit, IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo (FG), Viale Cappuccini 1, San Giovanni Rotondo, Italy
| | | | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Morelli F, Cisternino A, Capotorto A, Palomba G, Setola P, Maiello E. 8 SURGERY AFTER HIGH DOSE CHEMOTHERAPY FOR POOR RISK NON SEMINOMATOUS GERM CELL TUMORS (GCTs): A LONG FOLLOW UP. Cancer Treat Rev 2010. [DOI: 10.1016/s0305-7372(10)70034-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
44
|
Manzini VDP, Recchia L, Cafferata M, Porta C, Siena S, Giannetta L, Morelli F, Oniga F, Bearz A, Torri V, Cinquini M. Malignant peritoneal mesothelioma: a multicenter study on 81 cases. Ann Oncol 2010; 21:348-353. [PMID: 19635740 DOI: 10.1093/annonc/mdp307] [Citation(s) in RCA: 77] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023] Open
Affiliation(s)
- V de Pangher Manzini
- Division of Medical Oncology, Department of Internal Medicine and Oncology, Monfalcone Hospital, Monfalcone.
| | - L Recchia
- Division of Medical Oncology, Department of Internal Medicine and Oncology, Monfalcone Hospital, Monfalcone
| | - M Cafferata
- Division of Medical Oncology, Department of Internal Medicine and Oncology, Casale Monferrato Hospital, Casale Monferrato
| | - C Porta
- Department of Medical Oncology, Istituto di Ricovero e Cura a Carattere Scientifico, San Matteo University Hospital Foundation, Pavia
| | - S Siena
- The Falck Division of Medical Oncology, Niguarda Ca' Granda Hospital, Milan
| | - L Giannetta
- The Falck Division of Medical Oncology, Niguarda Ca' Granda Hospital, Milan
| | - F Morelli
- Department of Oncology, Istituto di Ricovero e Cura a Carattere Scientifico, Casa Sollievo della Sofferenza, San Giovanni Rotondo
| | - F Oniga
- Division of Medical Oncology, Department of Oncology, Venice-Mestre Hospital
| | - A Bearz
- Department of Medical Oncology, Centro di Riferimento Oncologico - Istituto di Ricovero e Cura a Carattere Scientifico, Aviano
| | - V Torri
- Department of Oncology, Mario Negri Institute, Milan, Italy
| | - M Cinquini
- Department of Oncology, Mario Negri Institute, Milan, Italy
| |
Collapse
|
45
|
Morelli F, Piano A, Criconia GM, Fanelli R, Caparrotti S, Maiello E. Malignant melanoma metastatic to the right atrium: clinical findings of an asyntomatic case. Minerva Cardioangiol 2008; 56:708-709. [PMID: 19092750] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/27/2023]
|
46
|
Morelli F, Piano A, Capotorto A, Tozzi L, Ronga S, Valori V, Maiello E. High-dose chemotherapy as initial salvage treatment in relapsed testicular cancer patients. EJC Suppl 2008. [DOI: 10.1016/j.ejcsup.2008.06.050] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
47
|
Morelli F, Raguso A, Piano A, Troiano M, Palomba G, Nanni L, Di Bisceglie M, Parisi S, Maiello E. Radiochemotherapy for anal carcinoma: Our experience. EJC Suppl 2008. [DOI: 10.1016/j.ejcsup.2008.06.043] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
|
48
|
Cugini P, Morelli F, Guagnano MT, Sensi S. A methodologically comprehensive approach to blood pressure 24‐hour pattern in essential obesity. BIOL RHYTHM RES 2008. [DOI: 10.1080/09291019409360300] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Affiliation(s)
- P. Cugini
- a Medical Semeiotic and Methodology (Chronobiology Unit) , University of Rome “La Sapienza” ,
- b c/o II Clinica Medica , 00161, Policlinico Umberto I, Rome, Italy Phone: Fax:
| | - F. Morelli
- a Medical Semeiotic and Methodology (Chronobiology Unit) , University of Rome “La Sapienza” ,
| | - M. T. Guagnano
- c Internal Medicine Institute , University G. D'Annunzio , Chieti, Italy
| | - S. Sensi
- c Internal Medicine Institute , University G. D'Annunzio , Chieti, Italy
| |
Collapse
|
49
|
Morelli F, Tozzi L, Setola P, Bisceglia M, Barbini VR, Maiello E. Postchemotherapy residual masses in germ cell tumor patients: our experience. Ann Oncol 2008; 17 Suppl 7:vii132-6. [PMID: 16760276 DOI: 10.1093/annonc/mdl966] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND The nature of post-chemotherapy tumor residuals can be determined only by excision and histological examination, but at present no consensus has been reached as to whether all patients with residual masses should undergo adjunctive surgery. PATIENTS AND METHODS Between August 1991 and September 2004, 120 patients with metastatic germ cell tumors were diagnosed at our hospital and 35 of these patients (30%) underwent adjunctive surgery after cisplatin-based chemotherapy. If serum tumor markers were still raised salvage chemotherapy was administered. RESULTS At the time of surgical intervention 30 patients (86%) had a partial remission with normal markers. Necrosis, differentiated teratoma and undifferentiated tumor were found in nine (30%), 19 (63%) and two (7%) of all patients. Five patients (14%) underwent postchemotherapy resections after second-line cisplatin-based combination chemotherapy. Four of the 35 patients died as a result of their malignant germ cell tumor. The median observation time after the initial diagnosis was 99 months (range 15-172 months). CONCLUSIONS Secondary resection of residual masses after first or second-line chemotherapy is still an essential part of the treatment of metastatic testicular cancer. Resection of mature teratoma or viable cancer adds to long-term event-free and overall survival in these patients.
Collapse
Affiliation(s)
- F Morelli
- Department of Onco-Hematology, Oncology Unit, Department of Surgery Sciences, Urology Unit and Pathology Unit, IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy.
| | | | | | | | | | | |
Collapse
|
50
|
Pannone G, De Maria S, Zamparese R, Metafora S, Serpico R, Morelli F, Rubini C, Farina E, Carteni M, Staibano S, De Rosa G, Lo Muzio L, Bufo P. Prognostic value of human telomerase reverse transcriptase gene expression in oral carcinogenesis. Int J Oncol 2007; 30:1349-57. [PMID: 17487355 DOI: 10.3892/ijo.30.6.1349] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
Human telomerase reverse transcriptase (hTERT) gene expression in resected specimens of oral squamous cell carcinoma (OSCC) and their surrounding tissue, either apparently normal or clearly histologically dysplastic, was evaluated by both real-time RT-PCR and immunohisto-chemical protein analyses. The expression level of hTERT in oral dysplasia and in OSCC was markedly higher than in normal tissues. The correlation between hTERT expression in OSCC and clinico-pathological parameters or survival of OSCC patients was statistically analyzed. Our study demonstrates that there is no significant relationship between hTERT expression and classical clinico-pathological parameters. Interestingly, survival analysis showed both overexpressing cases and lower survival rate in the early stage of OSCC (p=0.03 for immunohistochemistry; p=0.04 for RT real-time PCR). The histological location of hTERT in these tumors has been discussed in the context of the cancer stem cell theory.
Collapse
Affiliation(s)
- G Pannone
- Department of Surgical Sciences, University of Foggia, Foggia, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|